MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects

被引：2

作者：

Ray, A. ^{[1
]}

Cui, D. ^{[2
]}

Lee, D. ^{[2
]}

Mangada, M. M. ^{[1
]}

Jones, J. ^{[2
]}

Bain, G. ^{[1
]}

Traber, P. G. ^{[3
]}

Vrishabhendra, L. H. ^{[4
]}

Krzeski, P. W. ^{[5
]}

Vande Casteele, N. ^{[6
,7
]}

Reardon, M. M. ^{[8
]}

Stern, T. P. ^{[9
]}

Soo, C. L. ^{[10
]}

Nguyen, H. ^{[11
]}

Rogers, B. N. ^{[12
]}

Linde, P. G. ^{[13
]}

机构：

[1] Morph Therapeut, Biol & Translat, Waltham, MA USA

[2] Morph Therapeut, Dmpk, Waltham, MA USA

[3] Univ Penn, Med, Philadelphia, PA 19104 USA

[4] Medpace CPU, Cincinnati, OH USA

[5] Medpace, Dept Med, Warsaw, Poland

[6] Alimentiv, Precis Med, San Diego, CA USA

[7] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA

[8] Morph Therapeut, Pharmacovigilance, Waltham, MA USA

[9] Morph Therapeut, Biostat, Waltham, MA USA

[10] Morph Therapeut, Clin Operat, Waltham, MA USA

[11] Morph Therapeut, Cmc, Waltham, MA USA

[12] Morph Therapeut, Res, Waltham, MA USA

[13] Morph Therapeut, Clin, Waltham, MA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷

关键词：

D O I：

10.1093/ecco-jcc/jjab076.430

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P306

引用

页码：S333 / S335

页数：4

共 8 条

[1] Full Target Engagement With Saturation of α4β7 Integrin Receptor Occupancy Resulting in Changes in Subset of Lymphocytes by MORF-057 Following 200 Mg Daily Dosing in Healthy Subjects
Chavan, Ajit
Choi, Michael Y.
Jones, John P.
Lee, Dooyoung
Mangada, Maloy M.
Hussain, Ali
Thosar, Shilpa
Cui, Dan
Wu, Yujun
Chae, Mimi S.
Soo, Carolyn L.
Nguyen, Hanh
JeBailey, Lellean
Ray, Adrian S.
Rogers, Bruce N.
Bain, Gerard
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S565 - S565
[2] Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor
Jones, J.
Lee, D.
Smukste, I.
Cui, D.
Bursavich, M. G.
Troast, D.
Zhong, C.
Wong, J. E.
Mangada, M. M.
Bain, G.
Lippa, B.
Ray, A. S.
Rogers, B. N.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S149 - S150
[3] GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects
Levesque, B.
Meadows, K. Taylor
Buch, A.
Flynn, M.
Peters, K.
Olson, A.
Shen, J.
Slee, D.
Van Biene, C.
Aranda, R.
Vande Casteele, N.
Opiteck, G.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S461 - S462
[4] Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
Jin, Byung Hak
Hong, Taegon
Yoo, Byung Won
Kim, Choon Ok
Kim, Dasohm
Kim, Youn Nam
Park, Min Soo
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (10):
[5] GB004, A NOVEL PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATOYR BOWEL DISEASE, LEADS TO GUT-TARGETED HIF-1ALPHA PATHWAY ENGAGEMENT IN A MULTIPLE DOSE STUDY IN HEATHY SUBJECTS
Levesque, Barrett G.
Meadows, Kristen Taylor
Buch, Akshay
Flynn, Michael
Peters, Kevin
Olson, Allan
Shen, Jinshan
Slee, Debbie
Van Biene, Courtney
Aranda, Richard
Vande Casteele, Niels
Opiteck, Gregory J.
GASTROENTEROLOGY, 2020, 158 (06) : S1202 - S1202
[6] KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers
Lickliter, Jason
Anderl, Janet
Kirk, Christopher J.
Wang, Jinhai
Bomba, Darrin
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[7] Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Spencer I. Danto
Negin Shojaee
Ravi Shankar P. Singh
Cheryl Li
Steven A. Gilbert
Zorayr Manukyan
Iain Kilty
Arthritis Research & Therapy, 21
[8] Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Danto, Spencer, I
Shojaee, Negin
Singh, Ravi Shankar P.
Li, Cheryl
Gilbert, Steven A.
Manukyan, Zorayr
Kilty, Iain
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)

← 1 →